BCDA vs. GENE, ONVO, IKT, CHRO, COEP, SRNE, TVGN, CELZ, TTNP, and PALI
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Genetic Technologies (GENE), Organovo (ONVO), Inhibikase Therapeutics (IKT), Chromocell Therapeutics (CHRO), Coeptis Therapeutics (COEP), Sorrento Therapeutics (SRNE), Tevogen Bio (TVGN), Creative Medical Technology (CELZ), Titan Pharmaceuticals (TTNP), and Palisade Bio (PALI). These companies are all part of the "biological products, except diagnostic" industry.
Genetic Technologies (NASDAQ:GENE) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.
Genetic Technologies has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
Genetic Technologies has higher revenue and earnings than BioCardia.
0.6% of Genetic Technologies shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 6.5% of Genetic Technologies shares are owned by company insiders. Comparatively, 20.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Genetic Technologies has a net margin of 0.00% compared to Genetic Technologies' net margin of -2,425.79%. BioCardia's return on equity of 0.00% beat Genetic Technologies' return on equity.
BioCardia has a consensus target price of $4.00, suggesting a potential upside of 923.02%. Given Genetic Technologies' higher probable upside, analysts plainly believe BioCardia is more favorable than Genetic Technologies.
In the previous week, BioCardia had 5 more articles in the media than Genetic Technologies. MarketBeat recorded 9 mentions for BioCardia and 4 mentions for Genetic Technologies. Genetic Technologies' average media sentiment score of 0.61 beat BioCardia's score of 0.41 indicating that BioCardia is being referred to more favorably in the news media.
Genetic Technologies received 151 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 55.33% of users gave Genetic Technologies an outperform vote while only 47.62% of users gave BioCardia an outperform vote.
Summary
BioCardia beats Genetic Technologies on 8 of the 15 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
